VOGX (Vogenx Inc) stock: $17.45, $259.2M market cap, $0.2M cash, $259.0M EV, $313.5M fully diluted market cap. Next expected readout: Oct-27. Lead program: Mizagliflozin 5 mg (Postbariatric Hypoglycemia), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
The Company is a clinical-stage life science and drug development company focused on the discovery and development of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases associated with dysfunctions in human metabolism and high unmet medical needs.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.